The translocation t(8;16)(p11;p13) is associated with acute myeloid leukemia displaying monocytic differentiation (AML FAB M4/5) and fuses the MOZ (also named MYST3) gene (8p11) with the CBP (also named CREBBP) gene (16p13). Detection of the chimeric RNA fusions has proven difficult; only three studies have described successful amplification of the chimeric MOZ-CBP and CBP-MOZ fusions by reverse transcriptasepolymerase chain reaction (RT-PCR). We analyzed four cases of AML M4/5 with t(8;16)(p11;p13) by RT-PCR and fluorescence in situ hybridization (FISH) and characterized the reciprocal RNA fusions from three cases. We cloned both genomic translocation breakpoints from one case by long-range PCR and successfully applied RT-PCR to monitor minimal residual disease (MRD) between clinical complete remission and relapse. In three cases, the genomic breakpoints occurred in MOZ intron 16 and CBP intron 2. In one case, no fusion transcript was detected. The available data suggest clustering of t(8;16)(p11;p13) breakpoints in these introns leading to reciprocal in-frame MOZ exon 16/CBP exon 3 and in-frame CBP exon 2/MOZ exon 17 chimeric transcripts in the majority of cases. The described RT-PCR strategy may be valuable both for the routine detection of the t(8;16)(p11;p13) as well as for monitoring of MRD in this prognostically unfavorable patient group.
Introduction
The translocation t(8;16)(p11;p13) is a recurring aberration that occurs in both de novo and treatment-related (t)-acute myeloid leukemia (AML) and is associated with (myelo-) monocytic differentiation (AML FAB M4/5), erythrophagocytosis by the leukemic cells and a poor prognosis. [1] [2] [3] [4] [5] [6] [7] [8] [9] Both genes, MOZ (8p11) and CBP (16p13), involved in this specific translocation belong to the family of histone acetyltransferases with characteristics of transcriptional coregulators, and aberrant histone acetylation is believed to mediate leukemogenesis in this disease entity. 10, 11 The approved Human Genome Organization Nomenclature is CREBBP for CBP and MYST3 for MOZ. Reverse transcriptase-polymerase chain reaction (RT-PCR) strategies for the detection of the chimeric MOZ-CBP and CBP-MOZ fusion transcripts have largely been unsuccessful, 2, 9, 10 and thus, only four cases so far have been analyzed by RT-PCR. 10, 12, 13 The aim of this study was to develop a reliable RT-PCR for both the routine detection of reciprocal CBP and MOZ chimeric transcripts as well as the monitoring of minimal residual disease (MRD).
Case reports
The FAB subtype was determined in all patients according to standard morphological, cytological and immunological criteria. Erythrophagocytosis by the leukemic cells, a common feature in AML with t(8;16)(p11;p13), was noted in case 4 only. The FAB types and results of the cytogenetic analyses are shown in Table 1 .
Case 1
A 58-year-old woman was diagnosed with de novo AML in March 2002 . No response to induction chemotherapy with idarubicine and cytosine arabinoside was observed; however, after second-line therapy with high-dose cytosine arabinoside and mitoxantrone the patient achieved a complete remission (CR). Owing to severe neurological complications (ataxia and aphasia), most likely related to chemotherapy, no further therapies were initiated. The patient relapsed in March 2003 and achieved only a partial remission after an alternative reinduction chemotherapy with amsacrine and cytosine arabinoside: she died of persisting disease in September 2003.
Case 2
In January 1995, a 13-year-old karyotypic male, phenotypic female patient with bilateral ovarian dysgerminoma underwent surgery and was treated with four courses of BEP (bleomycin, etoposide, and cisplatin) and achieved a CR. In June 1996, t-AML was diagnosed. After induction and consolidation chemotherapy (cytosine arabinoside, mitoxantrone, idarubicine, fludarabine), autologous stem cell transplantation was performed and she has stayed in CR since then.
Case 3
A 78-year-old woman without any history of previous exposure to chemotherapy was diagnosed with AML in March 1995. Because of acute myocardial infarction no aggressive chemotherapy was initiated, and she died of persisting disease and septicemia in June 1995.
Case 4
A 31-year-old man was diagnosed with common acute lymphoblastic leukemia (c-ALL) FAB L2 in 1994. The mother of the patient had died of acute leukemia at the age of 36 years. The bone marrow (BM) karyotype was: 46, XY, del(9)(p22); rearrangement of the IgH-and TCR-g genes, but no BCR-ABL rearrangement was detected by molecular investigations. After induction chemotherapy according to the German ALL-BFM 90 protocol, the patient obtained CR. However, due to hematological and CNS relapse in March 1995, an alternative chemotherapy with high-dose cytosine arabinoside and mitoxantrone was initiated. In May 1995, the patient had only achieved a partial remission. An HLA-identical sibling (sister) bone marrow transplantation was successfully performed and the patient stayed in CR until December 1995. Then, because of pancytopenia, BM biopsy was performed and revealed secondary AML with erythrophagocytosis by the blast cells. The initial karyotype abnormality as well as the initial molecular rearrangements were not detectable any longer, but cytogenetic examination notably revealed a 46, XX, t(8;16)(p11;p13) karyotype suggesting that the leukemic clone was derived from the sibling BM donor. The patient succumbed to septicemia in January 1996. His sister, the marrow donor, has stayed free of leukemia.
Materials and methods

Cytogenetic and FISH analyses
Cytogenetic analysis was performed according to standard techniques. Slides were GTG-banded and karyotyped with a PSI image analysis system (PSI, Halladale, UK). Karyotypes were described according to the International System for Human Cytogenetic Nomenclature (ISCN 1995). 14 FISH analysis was performed using cosmids RT53, RT166, RT203, and RT191 that cover the CBP breakpoint region on chromosome 16 (Figures 1 and 2) . 2, 8 The position of the cosmid probes in the genomic CBP breakpoint region was mapped according to publicly available sequence data ( Figure 2 ). Dualcolor FISH was performed with a probe cocktail containing digoxigenin-labelled RT53/RT166 and biotin-labelled RT203/ RT191. For immunodetection of the probes, sheep antidigoxigenin-FITC (1:100) (Roche Diagnostics, Mannheim, Germany), Cy3-conjugated mouse anti-biotin (1:300) (Jackson Immuno Research Laboratories, Inc., USA) and rabbit antisheep-FITC (1:100) (Roche Diagnostics, Mannheim, Germany) were used. 
Genomic long template PCR
DNA was extracted from bone marrow cells according to standard protocols. 15 For the detection of the genomic translocation breakpoints, nested PCR was applied using the Expand Long Template PCR System (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions (system 3) and the primers listed in Table 2 . PCR conditions included denaturation for 2 min at 941C, 30 cycles of 10 s at 941C, 30 s at 601C and 4 min at 681C, followed by a final extension for 7 min at 681C. A volume of 8 ml of the PCR products were analyzed by gel electrophoresis through 0.8% ethidium bromide-stained agarose gels. PCR amplified fragments were purified from the gels using the Qiagen gelextraction kit (Qiagen, Hilden, Germany) and directly sequenced with an ABI Prism 310 genetic analyzer. Sequence analysis was performed using the BLAST program (http:// www.ncbi.nlm.nih.gov/BLAST/).
RT-PCR
Total RNA was extracted using the Qiagen RNeasy kit (Qiagen, Hilden, Germany). An amount of 2 mg of total RNA was reversetranscribed with the Taq Man Reverse Transcription kit (MuLV reverse transcriptase) according to the manufacturer's instructions (Applied Biosystems, Foster City, CA, USA). RT-PCR was carried out using a modified assay for the detection of MOZ and CBP fusion transcripts. 12 Reaction A, a one-step RT-PCR reaction designed to detect MOZ-CBP chimeras, contained the primers MOZ3558F and CBP1201R. It should be noted that in the initial report by Panagopoulos et al, 12 primer CBP1201R Figure 2 Position of CBP exons 1-18 and the cosmid probes used for FISH in the genomic CBP breakpoint region. A splitting signal of RT166 is consistent with a breakpoint in CBP intron 2 (see text). Owing to the position of CBP exon 3 located between RT166 and RT203, separated FISH signals of both cosmids are indicative of breakpoints in CBP intron 2 or 3 in the vicinity of exon 3. The position of 4 previously reported genomic breakpoints 16 (designated case 1-4 in this figure, one arrow due to their vicinity) and case 1 of this study (designated case 5 in this figure) are indicated by vertical arrows. The horizontal arrow indicates the translation start of CBP in exon 2. RT53 has been mapped centromeric to RT166; 2, 8 however, due to lack of DNA sequence information, its exact position in this contig remains unknown. The GenBank Accession Numbers for the cosmids are: RT166 ¼ AC005564; RT191 ¼ AC004509; RT 203 ¼ AC004495. These sequences were aligned with a 500 kb chromosome 16p13.3 Celera Genomics contig comprising the CBP region. MOZ cDNA: Accession Number U47742; CBP cDNA: Accession Number NM_004380. -GTTGCAATTGCTTGTGTGGG-TAC-3 0 . Reaction B, a nested RT-PCR reaction for the detection of CBP-MOZ chimeras comprised the primers CBP96F and MOZ3953R (first step) and CBP174F and MOZ3844R (second step). PCR conditions and primers (except CBP1201) were exactly as previously described. 12 Reaction C, a one-step RT-PCR reaction using the primers MOZ3536F and CBP404R, was introduced to increase the sensitivity for the detection of the MOZ-CBP type I chimeric transcripts (see below). All primers used in this study are listed in Table 2 . PCRs were carried out in 50 ml reaction volumes containing 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 2 mM MgCl 2 , 0.2 mM of each dNTP, 1.25 U AmpliTaq DNA Polymerase (Applied Biosystems, Foster City, CA, USA), 4 ml of cDNA and 1 mM of each of the primers MOZ3536F and CBP404R. PCR reactions were performed in a Gene Amp PCR System 9700 thermocycler (Perkin Elmer, Applied Biosystems, Vienna). After an initial denaturation at 951C for 6 min, 35 cycles of 1 min at 951C, 1 min at 601C, and 1 min at 721C were performed, followed by a final extension for 10 min at 741C. DNA sequencing of PCR amplified fragments was performed as described above.
RT-PCR and
FISH analysis of AML with t(8;16)(p11;p13) HH Schmidt et al was described in the wrong orientation and was replaced in this study by primer CBP1201R 5 0
Results
FISH
Using CBP-specific cosmid clones (Figure 1 ) two types of hybridization patterns were observed: first, separated signals of the probe combinations RT53/RT166 and RT203/RT191 on the der(8) and der(16) chromosomes respectively, were observed in patients 1, 2 and 4. This constellation is consistent with a breakpoint in CBP intron 2 or 3 (Figures 1 and 2 ). Second, a splitting signal of the probe combination RT53/RT166 on the der(8) and der(16) chromosomes, respectively, was seen in patient 3, indicative for a breakpoint in CBP intron 1 or 2 (Figures 1 and 2 ).
RT-PCR
RT-PCR reaction A yielded a B1100 bp fragment (type I transcript) and a B410 bp fragment (type II transcript) in case 1 but not the other cases. Sequence analysis showed that in the type I transcript, nucleotide (nt) 3745 of MOZ was fused inframe with nt 284 of CBP. In the type II transcript, nt 3745 of MOZ was fused out-of-frame with nt 997 of CBP. Reaction C, specifically designed to increase the amplification sensitivity of the MOZ-CBP type I transcript, yielded a 353 bp fragment in patients 1, 2 and 3; and sequence analysis again revealed a type I in-frame fusion of nt 3745 of MOZ with nt 284 of CBP. Reaction B amplified a 230 bp CBP-MOZ chimeric transcript in patients 1, 2 and 3 fusing nt 283 of CBP in-frame with nt 3746 of MOZ. Both types of MOZ-CBP fusions as well as the CBP-MOZ fusion in patients 1, 2 and 3 were exactly the same as in two previously described cases, 12 confirming that they are a recurring feature of t(8;16)(p11;p13). Although FISH analysis of case 4 suggested a breakpoint in CBP intron 2 or 3, neither a MOZ-CBP nor a CBP-MOZ chimeric transcript was observed in this patient using all described RT-PCR reactions. As alternative breakpoints in MOZ exon 17 have been described in two cases, 10, 13 we applied nested RT-PCR using two pairs of MOZ exon 17 forward primers (MOZ4379F, MOZ4421F and MOZ4791F, MOZ4831F) combined with one pair of CBP exon 4 and 5 reverse primers (CBP1023R, CBP1159R) ( Table 2) . These reactions were designed to cover approximately the first 1500 bp of the large (44 kb) MOZ exon 17 ( Figure 4) ; however, no amplification products were obtained. If the fusions in this case were not missed for technical reasons, these data suggest a MOZ breakpoint either upstream of the MOZ exon 16 primers used or more downstream in MOZ exon 17 than in the previously published cases.
10,13
Genomic breakpoints
No data on the genomic breakpoints of t(8;16)(p11;p13) positive leukemias were available at the beginning of our analysis. The reciprocal nature of the fusion transcripts at nt 283/284 of CBP and 3745/3746 of MOZ suggested a genomic breakpoint in the corresponding intervening intronic regions. It was recently shown that nucleotides 3745 and 3746 of MOZ correspond to the end of exon 16 and the beginning of exon 17, respectively, 16 and nt 283 and 284 of CBP to the end of exon 2 and the beginning of exon 3, respectively 12 ( Figure 3) . By searching the databases and carrying out alignments of the MOZ (Accession Number U47742) and CBP (Accession Number NM_004380) cDNAs to genomic DNA, we identified a 2389 bp MOZ intron 16 (Accession Number AC090571) and a 28812 bp CBP intron 2 (Accession Number AC005564) as candidate breakpoint regions (Figure 4 ). CBP exon 3 extends from nt 284 to nt 997; thus, exon 3 was spliced out in the type II MOZ-CBP fusion transcript (Figure 3 ). Nested long template PCR was applied to detect the genomic rearrangements. In order to cover the 28.8 kb CBP intron 2, we used a pair of constant MOZ reverse primers with three pairs of CBP exon 2 and intron 2, forward primers. The combination of CBPintr20168 and MOZ3976R and nested PCR with CBPintr20308 and MOZ3906R yielded a 3 kb genomic fragment (der(16) breakpoint) from case 1 but not from normal control DNA. The reciprocal rearrangement (der(8) breakpoint), a 1.2 kb genomic fragment, was amplified using long-range PCR with the primers MOZintr795 and CBPintr23786 and nested PCR with MOZintr863 and CBPintr23650 (data not shown). Sequence analysis using various primers revealed that the genomic CBP-MOZ junctions were located at nt 22423 of CBP intron 2, and at nt 926 of MOZ intron 16. In the reciprocal MOZ-CBP rearrangement, the breakpoints were found at nt 916 of MOZ intron 16 and nt 22420 of CBP intron 2. Thus, a Figure 3 Schematic representation of the MOZ-CBP and CBP-MOZ chimeric transcripts. The positions of the primers (Table 2) are indicated. duplication of 4 nt (GCAC), presumably derived from chromosome 16, and a deletion of 9 nt of chromosome 8 accompanied the translocation. Breakpoints in MOZ intron 16 and CBP intron 2 were also described in a recently published study; 16 however, the CBP breakpoint in our case was located 18-20 kb telomeric from the four published cases (Figure 4 ).
Minimal residual disease
The RT-PCR assays were also applied to monitor minimal residual disease in case 1. After the patient had achieved a CR, peripheral blood samples were obtained at 2-month intervals. Neither MOZ-CBP fusions type I or II nor CBP-MOZ fusions were detected in any of the samples tested by RT-PCR (Reactions A-C). In January 2003, still in clinical CR, MOZ-CBP fusions type I and CBP-MOZ fusions again became detectable in the peripheral blood (Reactions B and C). After 7 weeks, clinical relapse was diagnosed and confirmed by RT-PCR. Discussion t(8;16)(p11;p13) is a frequent aberration in AML displaying (myelo)monocytic differentiation and so far 47 cases have been reported. 17 Although several studies demonstrated breakpoints in the CBP and MOZ regions by means of FISH and Southern blotting, 2, 10 RT-PCR analysis of t(8;16)(p11;p13) positive leukemias has proven difficult. So far, only three studies described successful amplification of the fusion transcripts by RT-PCR. 10, 12, 13 These investigations revealed in-frame MOZ exon 16/CBP exon 3 and in-frame CBP exon2/MOZ exon 17 chimeric transcripts in two cases. 12 Breakpoints within exon 17 of MOZ and presumably intron 3 of CBP leading to in-frame MOZ-CBP fusion RNAs have been described in another two cases. The reciprocal CBP-MOZ fusion was either out-of-frame, 10 or not found, 13 suggesting that the MOZ-CBP fusion is the critical event in leukemogenesis. We confirmed these specific fusions in three additional cases; furthermore, the reciprocal genomic breakpoints (MOZ intron 16, CBP intron 2) in two recently analyzed cases 16 that were not investigated by RT-PCR are also consistent with these fusion transcripts. In six out of seven previously published cases, FISH notably revealed CBP rearrangements located at the telomeric end of cosmid RT166. 2 This cosmid comprises CBP exons 1-3, the ATG start codon is located in exon 2. At the telomeric end, RT166 exceeds CBP exon 3 for approximately 700 bp (Figure 2 ). Thus, under the assumption that replacement of the initial ATG codon is necessary for the creation of a fusion protein, a splitting signal of RT166 is consistent with a breakpoint in CBP intron 2. Three of these six cases were investigated by Southern blot analysis using a MOZ cDNA probe (nt 4312-4764) and all cases showed MOZ rearrangements located within a 6 kb BamHI fragment encompassing part of MOZ intron 15, exon 16, intron 16 and the first 1200 bp of exon 17 ( Figure 4) . 2 Thus, the available data suggest that the majority of t(8;16)(p11;p13) cases are characterized by the above-described MOZ exon 16/CBP exon 3 and CBP exon 2/MOZ exon 17 chimeric transcripts (Figure 3) . The incidence and clustering of alternative breakpoints awaits further investigation.
Including case 1 of this study, five genomic t(8;16) breakpoints have been characterized at the sequence level. 16 While all reported MOZ breakpoints cluster within 3 kb of genomic DNA, the CBP breakpoints are dispersed over the 28.8 kb CBP intron 2 ( Figure 4) . Southern blot analysis of two previously reported cases showed CBP rearrangements located at the telomeric 8 kb of cosmid RT166, consistent with CBP intron 2 breakpoints in the vicinity of those observed in case 1.
2 A similar breakpoint can be predicted from RT-PCR analysis and FISH hybridization pattern (type I) in case 2 of this study. Thus, scattering of the genomic CBP breakpoints presumably precludes genomic PCR assays for the routine detection of t(8;16)(p11;p13) rearrangements and explains the two different FISH hybridization patterns of the described CBP cosmids. 2 A recent investigation of four genomic t(8;16)(p11;p13) breakpoints revealed additional changes like deletions, duplica- Figure 4 Restriction map of the breakpoint cluster regions in AML with t(8;16)(p11;p13). Four previously reported breakpoints 16 (designated case 1-4 in this figure) and the breakpoint of case 1 of this study (designated case 5 in this figure) were sequenced at the genomic level. The position of the breakpoints in case 6 13 and 7 10 was determined by cDNA analysis of MOZ-CBP chimeras. In both cases, MOZ exon 17 was broken and fused in-frame to CBP exon 3, suggesting genomic breakpoints in CBP intron 3. The MOZ cDNA fragment (nt 4312-4764) and the MOZ intronic fragment have been used in previous studies to detect rearrangements in the MOZ region by Southern blot.
2,10 GenBank Accession Numbers: CBP intron 2: AC005564; MOZ intron 16: AC090571; cases 1-4 16 : AJ315151 -AJ315158; case 5: AY442917, AY442918; MOZ intron fragment: AF012283. Restriction enzymes:
tions and insertions at the breakpoint junctions. 16 Similarly, in case 1 of this study, the translocation did not originate through a simple end-to-end fusion. The observed duplication and deletion suggest multiple DNA breaks and support the theory that a DNA damage repair mechanism is involved in the pathogenesis of t(8;16)(p11;p13) translocations. 16 The CBP gene is known to have promiscuous translocation partners. Apart from MOZ, CBP is also fused to MLL by the t(11;16)(q23;p13) in treatment-related hematologic malignancies. 18 (Figure 2 ) also in this entity. All reported MLL/CBP fusions have been treatment-related, whereas only a fraction of CBP/MOZ chimeras occurred after exposure to chemotherapy. The different breakpoint clusters in both entities do not support the theory that either CBP intron 2 or 3 is especially prone to DNA-damaging effects of cytostatic drugs, the breakpoint heterogeneity might also be a prerequisite for the maintenance of an open reading frame in the different fusion proteins.
We have established a more sensitive RT-PCR assay for the detection of the MOZ exon 16/CBP exon 3 fusion transcript (Figures 3 and 5) . As the reverse primer of this reaction is located in CBP exon 3, the assay is unable to detect the MOZ-CBP type II transcript (Figure 3) , which, however, was out-of-frame and therefore presumably does not contribute to leukemogenesis. 12 This assay, together with the previously published RT-PCR reaction for the CBP-MOZ fusion, 12 enabled us to detect the reciprocal fusions in three out of four cases investigated. Thus, RT-PCR may be useful for the routine detection of t(8;16)(p11;p13) positive leukemias and may help to establish the real incidence of this aberration in AML FAB M4/À5. In many types of hematologic neoplasms, molecular assays for the monitoring of specific chromosomal aberrations have become part of the clinical routine. For the first time in AML with t(8;16)(p11;p13), we have successfully monitored MRD by RT-PCR. A sensitive monitoring of the malignant clone may help to guide treatment decisions and eventually improve the treatment outcome of this prognostically unfavorable patient group.
Figure 5
Ethidium bromide-stained agarose gels showing dilution experiments with the RT-PCR reactions A-C. Patient RNA from case 1 at initial diagnosis was diluted into HL60 RNA as negative control and reverse-transcribed. The dilution was performed in 10-fold steps, from undiluted to 10
À6
. A tube without RNA was used as negative control (H 2 O). Target sensitivity was 10 À1 and 10 À3 in the one-step reactions A and C, respectively (MOZ-CBP type I transcript) and 10 À4 in the nested reaction B (CBP-MOZ transcript).
